With a baby on the way, Nathan Kirkland was facing a rare, aggressive form of bile duct cancer. Kirkland’s bills piled up as ...

Bile duct cancer cells and normal cells 3D photolithography image difference Bile duct cancer, a malignant tumor that occurs in the bile duct, is difficult to diagnose early because there are few ...

It's a deadly cancer with a complicated name and for too long there've been limited treatment options for sufferers, until ...

Adjuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...

The National Cancer Institute and University of Oxford report that oral contraceptive use is not associated with increased ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Of 1.3 million participants in the MWS with a median follow-up of 21.4 years, 2,765 (o.21%) developed liver cancer, with no association emerging between ever-use of oral contraceptives and liver ...

Cholangiocarcinoma (CCA) is the second leading cause of primary liver cancer in the world. In the last five years the approach to CCA has moved toward radiological and histological diagnosis and ...

Oncology nurses can advocate for patients with cholangiocarcinoma to participate in on-going clinical trials with tinengotinib.